Monsanto plans to sell Posilac business

Aug. 8, 2008 - - Monsanto Company plans to divest its Posilac dairy hormone business to focus on genetically modified crops. Monsanto has marketed Posilac, also known as recombinant bovine somatotropin or rBST, since 1994. The company has not detailed Posilac sales or profit, spokeswoman Danielle Jany said. “While POSILAC is a strong product for the business, we believe repositioning the business with a strategic owner will allow Monsanto to focus on the growth of its core seeds and traits business while ensuring that loyal dairy farmers continue to receive the value of POSILAC in their operations,” said Carl Casale, Monsanto’s executive vice president of strategy and operations.